---
document_datetime: 2025-12-02 05:29:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-acetylsalicylic-acid-viatris.html
document_name: clopidogrel-acetylsalicylic-acid-viatris.html
version: success
processing_time: 0.1295057
conversion_datetime: 2025-12-24 17:28:04.709657
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan)

[RSS](/en/individual-human-medicine.xml/67268)

##### Authorised

This medicine is authorised for use in the European Union

clopidogrel / acetylsalicylic acid Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan)](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76247)
- [Related content](#related-content-1576)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Clopidogrel/Acetylsalicylic acid Mylan is a medicine used to prevent problems caused by blood clots and hardening of the arteries, such as a heart attack, in adults who are already taking both clopidogrel and acetylsalicylic acid as separate tablets. It can be used in the following groups of patients who have a condition known as 'acute coronary syndrome':

- patients who have unstable angina (a severe type of chest pain) or who have had a heart attack with no 'ST-segment elevation' (an abnormal reading on an electrocardiogram), including those who are having a stent (a short tube) inserted into an artery to prevent it from closing up;
- patients being treated for heart attack with ST-segment elevation, when the doctor thinks that they would benefit from thrombolytic treatment (treatment to dissolve blood clots).

Clopidogrel/Acetylsalicylic acid Mylan contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin) and is a 'generic medicine'. This means that Clopidogrel/Acetylsalicylic acid Mylan contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called DuoPlavin.

Expand section

Collapse section

## How is Clopidogrel/Acetylsalicylic acid Mylan used?

The medicine is available as tablets containing 75 mg clopidogrel, either with 75 mg or 100 mg acetylsalicylic acid and can only be obtained with a prescription. The medicine is taken as one tablet once a day instead of the clopidogrel and acetylsalicylic acid tablets that the patient has already been taking separately.

For more information about using Clopidogrel/Acetylsalicylic acid Mylan, see the package leaflet or contact your doctor or pharmacist.

## How does Clopidogrel/Acetylsalicylic acid Mylan work?

Both active substances in the medicine, clopidogrel and acetylsalicylic acid, are antiplatelet medicines. This means that they help to prevent components in the blood called platelets from sticking together and forming clots, thus helping to prevent another heart attack.

Clopidogrel blocks a substance called ADP from attaching to a receptor (target) on the surface of platelets. This stops the platelets becoming 'sticky', reducing the risk of a blood clot forming.

Acetylsalicylic acid blocks an enzyme called prostaglandin cyclo-oxygenase. This reduces the production of a substance called thromboxane, which normally helps clots to form by attaching platelets together. The combination of the two active substances reduces the risk of blood clots forming more than either medicine alone.

Both active substances have been available in the EU for a number of years. Clopidogrel has been authorised since 1998 as an antiplatelet medicine, and is often used in combination with acetylsalicylic acid. Acetylsalicylic acid has been available for over 100 years.

## How has Clopidogrel/Acetylsalicylic acid Mylan been studied?

Studies on the benefits and risks of the active substances in the authorised uses have already been carried out with the reference medicine, DuoPlavin, and do not need to be repeated for Clopidogrel/Acetylsalicylic acid Mylan.

As for every medicine, the company provided studies on the quality of Clopidogrel/Acetylsalicylic acid Mylan. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Clopidogrel/Acetylsalicylic acid Mylan?

The European Medicines Agency concluded that, in accordance with EU requirements, Clopidogrel/Acetylsalicylic acid Mylan has been shown to have comparable quality and to be bioequivalent to DuoPlavin. Therefore, the Agency's view was that, as for DuoPlavin, the benefits of Clopidogrel/Acetylsalicylic acid Mylan outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Clopidogrel/Acetylsalicylic acid Mylan?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Clopidogrel/Acetylsalicylic acid Mylan have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Clopidogrel/Acetylsalicylic acid Mylan are continuously monitored. Side effects reported with Clopidogrel/Acetylsalicylic acid Mylan are carefully evaluated and any necessary action taken to protect patients.

## Other information about Clopidogrel/Acetylsalicylic acid Mylan

Clopidogrel/Acetylsalicylic acid Mylan received a marketing authorisation valid throughout the EU on 09 January 2020.

Clopidogrel / Acetylsalicylic acid Mylan : EPAR - Medicine overview

Reference Number: EMA/628773/2019

English (EN) (178.91 KB - PDF)

**First published:** 24/01/2020

[View](/en/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-589)

български (BG) (203.95 KB - PDF)

**First published:**

24/01/2020

[View](/bg/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_bg.pdf)

español (ES) (178.15 KB - PDF)

**First published:**

24/01/2020

[View](/es/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (202.22 KB - PDF)

**First published:**

24/01/2020

[View](/cs/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (177.72 KB - PDF)

**First published:**

24/01/2020

[View](/da/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (182.58 KB - PDF)

**First published:**

24/01/2020

[View](/de/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (165.08 KB - PDF)

**First published:**

24/01/2020

[View](/et/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (206.03 KB - PDF)

**First published:**

24/01/2020

[View](/el/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_el.pdf)

français (FR) (179.57 KB - PDF)

**First published:**

24/01/2020

[View](/fr/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (199.94 KB - PDF)

**First published:**

24/01/2020

[View](/hr/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (176.2 KB - PDF)

**First published:**

24/01/2020

[View](/it/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (219.03 KB - PDF)

**First published:**

24/01/2020

[View](/lv/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (209.06 KB - PDF)

**First published:**

24/01/2020

[View](/lt/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (201.41 KB - PDF)

**First published:**

24/01/2020

[View](/hu/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (202.78 KB - PDF)

**First published:**

24/01/2020

[View](/mt/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (177.98 KB - PDF)

**First published:**

24/01/2020

[View](/nl/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (204.17 KB - PDF)

**First published:**

24/01/2020

[View](/pl/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_pl.pdf)

português (PT) (179.08 KB - PDF)

**First published:**

24/01/2020

[View](/pt/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_pt.pdf)

română (RO) (198.58 KB - PDF)

**First published:**

24/01/2020

[View](/ro/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (201.21 KB - PDF)

**First published:**

24/01/2020

[View](/sk/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (198.26 KB - PDF)

**First published:**

24/01/2020

[View](/sl/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (176.13 KB - PDF)

**First published:**

24/01/2020

[View](/fi/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (176.26 KB - PDF)

**First published:**

24/01/2020

[View](/sv/documents/overview/clopidogrel-acetylsalicylic-acid-mylan-epar-medicine-overview_sv.pdf)

Clopidogrel / Acetylsalicylic acid Mylan : EPAR - Risk-management-plan

English (EN) (3.65 MB - PDF)

**First published:** 24/01/2020

**Last updated:** 04/03/2024

[View](/en/documents/rmp/clopidogrel-acetylsalicylic-acid-mylan-epar-risk-management-plan_en.pdf)

## Product information

Clopidogrel / Acetylsalicylic acid Viatris : EPAR - Product information

English (EN) (434.35 KB - PDF)

**First published:** 24/01/2020

**Last updated:** 05/05/2025

[View](/en/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-472)

български (BG) (701 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/bg/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_bg.pdf)

español (ES) (387.71 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/es/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_es.pdf)

čeština (CS) (483.86 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/cs/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_cs.pdf)

dansk (DA) (374.54 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/da/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_da.pdf)

Deutsch (DE) (433.4 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/de/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_de.pdf)

eesti keel (ET) (399.47 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/et/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (483.97 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/el/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_el.pdf)

français (FR) (460.58 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/fr/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (571.6 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/hr/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_hr.pdf)

íslenska (IS) (366.55 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/is/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_is.pdf)

italiano (IT) (494.22 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/it/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (443.7 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/lv/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (446.62 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/lt/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_lt.pdf)

magyar (HU) (602.93 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/hu/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_hu.pdf)

Malti (MT) (345.76 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/mt/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (404.68 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/nl/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_nl.pdf)

norsk (NO) (374.6 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/no/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_no.pdf)

polski (PL) (599.09 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/pl/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_pl.pdf)

português (PT) (436.29 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/pt/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_pt.pdf)

română (RO) (586.75 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/ro/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (400.72 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/sk/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (352.42 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/sl/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_sl.pdf)

Suomi (FI) (559.28 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/fi/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_fi.pdf)

svenska (SV) (321.17 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

05/05/2025

[View](/sv/documents/product-information/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000268788 02/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Clopidogrel / Acetylsalicylic acid Viatris : EPAR - All Authorised presentations

English (EN) (160.39 KB - PDF)

**First published:** 24/01/2020

**Last updated:** 17/01/2024

[View](/en/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-941)

български (BG) (70.4 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/bg/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.65 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/es/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (28.64 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/cs/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.79 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/da/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (54.79 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/de/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (49.49 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/et/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (49.28 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/el/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (19.34 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/fr/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (124.28 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/hr/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (49.9 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/is/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (49.24 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/it/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (67.61 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/lv/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (94.87 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/lt/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (61.77 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/hu/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (39.92 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/mt/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (49.49 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/nl/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (38.53 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/no/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (51.27 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/pl/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (18.73 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/pt/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.42 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/ro/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (51.16 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/sk/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (44.05 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/sl/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (74.9 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/fi/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (38.44 KB - PDF)

**First published:**

24/01/2020

**Last updated:**

17/01/2024

[View](/sv/documents/all-authorised-presentations/clopidogrel-acetylsalicylic-acid-viatris-previously-clopidogrel-acetylsalicylic-acid-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan) Active substance

- acetylsalicylic acid
- clopidogrel hydrogen sulfate

International non-proprietary name (INN) or common name

- clopidogrel
- acetylsalicylic acid

Therapeutic area (MeSH)

- Acute Coronary Syndrome
- Myocardial Infarction

Anatomical therapeutic chemical (ATC) code B01AC30

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Clopidogrel/Acetylsalicylic acid Viatris is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Viatris is a fixed-dose combination medicinal product for continuation of therapy in:

## Authorisation details

EMA product number EMEA/H/C/004996

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Pharmaceuticals Limited

Damastown Industrial Park Mulhuddart Dublin 15 Ireland

Opinion adopted 14/11/2019 Marketing authorisation issued 09/01/2020 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Clopidogrel / Acetylsalicylic acid Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (310.14 KB - PDF)

**First published:** 03/03/2025

**Last updated:** 05/05/2025

[View](/en/documents/procedural-steps-after/clopidogrel-acetylsalicylic-acid-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Clopidogrel / Acetylsalicylic acid Viatris : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (610.56 KB - PDF)

**First published:** 21/09/2020

**Last updated:** 03/03/2025

[View](/en/documents/procedural-steps-after/clopidogrel-acetylsalicylic-acid-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Clopidogrel / Acetylsalicylic acid Mylan : EPAR  - Public assessment report

Adopted

English (EN) (1.72 MB - PDF)

**First published:** 24/01/2020

[View](/en/documents/assessment-report/clopidogrel-acetylsalicylic-acid-mylan-epar-public-assessment-report_en.pdf)

#### News on Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated) 15/11/2019

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Clopidogrel / Acetylsalicylic acid Viatris : EPAR - Product information - tracked changes

English (EN) (139.24 KB - DOCX)

**First published:** 05/05/2025

[View](/en/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_en.docx)

[Other languages (23)](#file-language-dropdown-625)

български (BG) (144.9 KB - DOCX)

**First published:**

05/05/2025

[View](/bg/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_bg.docx)

español (ES) (113.49 KB - DOCX)

**First published:**

05/05/2025

[View](/es/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_es.docx)

čeština (CS) (119.43 KB - DOCX)

**First published:**

05/05/2025

[View](/cs/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (121.43 KB - DOCX)

**First published:**

05/05/2025

[View](/da/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_da.docx)

eesti keel (ET) (119.15 KB - DOCX)

**First published:**

05/05/2025

[View](/et/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (130.46 KB - DOCX)

**First published:**

05/05/2025

[View](/el/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_el.docx)

français (FR) (121.95 KB - DOCX)

**First published:**

05/05/2025

[View](/fr/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (134.97 KB - DOCX)

**First published:**

05/05/2025

[View](/hr/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (109.38 KB - DOCX)

**First published:**

05/05/2025

[View](/is/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_is.docx)

italiano (IT) (116.29 KB - DOCX)

**First published:**

05/05/2025

[View](/it/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (116.65 KB - DOCX)

**First published:**

05/05/2025

[View](/lv/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (120.9 KB - DOCX)

**First published:**

05/05/2025

[View](/lt/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (130.42 KB - DOCX)

**First published:**

05/05/2025

[View](/hu/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (302.09 KB - DOCX)

**First published:**

05/05/2025

[View](/mt/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (106.14 KB - DOCX)

**First published:**

05/05/2025

[View](/nl/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (108.13 KB - DOCX)

**First published:**

05/05/2025

[View](/no/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_no.docx)

polski (PL) (123.36 KB - DOCX)

**First published:**

05/05/2025

[View](/pl/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_pl.docx)

português (PT) (118.7 KB - DOCX)

**First published:**

05/05/2025

[View](/pt/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_pt.docx)

română (RO) (111.03 KB - DOCX)

**First published:**

05/05/2025

[View](/ro/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (172.24 KB - DOCX)

**First published:**

05/05/2025

[View](/sk/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (116.9 KB - DOCX)

**First published:**

05/05/2025

[View](/sl/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (230.43 KB - DOCX)

**First published:**

05/05/2025

[View](/fi/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (110.5 KB - DOCX)

**First published:**

05/05/2025

[View](/sv/documents/product-information-tracked-changes/clopidogrel-acetylsalicylic-acid-viatris-epar-product-information-tracked-changes_sv.docx)

#### Related content

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/05/2025

## Share this page

[Back to top](#main-content)